ACC 2022 Late|breaking Clinical Trials Announced

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the ...

... clinical course or late-onset HCM). ... This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system.

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the ...

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive ...

Clinical Trial Results

C Michael Gibson present: newest clinical guidelines released for preventing ... Michael Gibson Discuss: Heart Failure Trials at AHA 2022 View Video. Dr ...

Press Releases | Medtronic

ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in ...

Gilead Announces Partial Clinical Hold for Studies Evaluating ...

The US Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine.

Philips at ACC 2023 - News | Philips

The positive clinical study results announced today are further ... American College of Cardiology (ACC) Late Breaking Clinical Trials.

What's Hot at ACC.22? Late-breaking Science Preview | Clinical Trials

What's hot at ACC.22? In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, ...

Heart failure with preserved ejection fraction update - PubMed Central

... clinical trials and provides therapeutic rationale for new treatment options. ... 2022 AHA/ACC/ HFSA Guideline for the Management of Heart Failure. J Card ...

Press Releases Details - Silence Therapeutics

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American ...

Biosense Webster Presents Late-Breaking Data from admIRE ...

Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting · Reddy VY, Calkins H, Mansour ...

Cleerly, Partners Announce TRANSFORM Trial

Cleerly's approach is grounded in nearly 20 years of science from landmark multi-center clinical trials. Cleerly enhances health literacy for each and every ...

Hybrid ACC.22 Resurrects the Live Scientific Session - Medscape

Morris said there had been 117 international submissions for what turned out to be 39 coveted spots on the meeting's Late-Breaking Clinical ...

ACC Cardiology Hour From AHA 2022 - YouTube

... clinical trials released during cardiology's biggest meetings. Visit ... ESC 22 Late-breaker Discussion: The ADVOR Trial. Radcliffe ...

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC ...

ANN ARBOR, Mich., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic ...

ACC Cardiology Hour From ACC.23 - Physician's Channel

Join Valentín Fuster, MD, PhD, MACC and a panel of experts for a discussion on the top late-breaking clinical trials released during the ACC 2023 Conference.

Late-breaking Data Demonstrate AHA/ACC Guideline-directed ...

– November 6, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results that show evaluating ...

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted ...

... Late-Breaking Presentation at ACC Meeting in April 2022 ... American Medical Association Late- Breaking Clinical Trials. Date ...

ACC.21 late-breaking clinical trial programme announced

ACC said that the late-breaking clinical trial sessions will explore the latest research in the areas of ischemic heart disease, prevention and ...

ESC Expert Insights at ACC.22 - European Society of Cardiology

... trials released during ACC.22 and their impact on clinical practice ... At a late-breaking session at ACC today, a well performed, small, randomized ...

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23 ...

Late-Breaking Clinical Trials Deep Dive II. Abstract: #LBA 413-15 ... In October 2022, Merck announced that STELLAR met its primary ...